{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T10:35:27Z","timestamp":1794479727244,"version":"4.9.1"},"reference-count":222,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.isci.2026.117255","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:48:25Z","timestamp":1791830905000},"page":"117255","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intelligent immunotherapy: AI-driven optimization of CAR-T therapy in hematologic malignancies"],"prefix":"10.1016","volume":"29","author":[{"given":"Farshid","family":"Farhadzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossien","family":"Borji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cena","family":"Aram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Alishvandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Javad","family":"Kamali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Rahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.117255_bib1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117255_bib2","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117255_bib3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117255_bib4","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Michael","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117255_bib5","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117255_bib6","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2026.117255_bib7","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2026.117255_bib8","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117255_bib9","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2026.117255_bib10","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117255_bib11","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.isci.2026.117255_bib12","doi-asserted-by":"crossref","first-page":"581.e1","DOI":"10.1016\/j.jtct.2022.05.026","article-title":"Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.isci.2026.117255_bib13","doi-asserted-by":"crossref","first-page":"77.e1","DOI":"10.1016\/j.jtct.2023.10.017","article-title":"Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis","volume":"30","author":"Jacobson","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.isci.2026.117255_bib14","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells","volume":"5","author":"Pennisi","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.isci.2026.117255_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15225443","article-title":"Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities","volume":"15","author":"de Boer","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.isci.2026.117255_bib16","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1182\/bloodadvances.2024014027","article-title":"EASIX and m-EASIX predict CRS and ICANS in pediatric and AYA patients after CD19-CAR T-cell therapy","volume":"9","author":"Zandaki","year":"2025","journal-title":"Blood Adv."},{"issue":"16_suppl","key":"10.1016\/j.isci.2026.117255_bib17","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.e13622","article-title":"Machine learning-based prediction of cytokine release syndrome post CAR-T cell therapy","volume":"43","author":"Paludo","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117255_bib18","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/bjh.18873","article-title":"Derivation and validation of a novel score for early prediction of severe CRS after CAR-T therapy in haematological malignancy patients: A multi-centre study","volume":"202","author":"Zhou","year":"2023","journal-title":"Br. J. Haematol."},{"issue":"Supplement 1","key":"10.1016\/j.isci.2026.117255_bib19","doi-asserted-by":"crossref","first-page":"7211","DOI":"10.1182\/blood-2024-204477","article-title":"Predictive Model for Infection Risk in CAR-T Therapy Patients","volume":"144","author":"An","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.117255_bib20","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/bloodadvances.2021004575","article-title":"CRP and ferritin in addition to the EASIX score predict CAR-T\u2013related toxicity","volume":"5","author":"Greenbaum","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.isci.2026.117255_bib21","doi-asserted-by":"crossref","first-page":"240.e1","DOI":"10.1016\/j.jtct.2025.01.888","article-title":"Prospective Validation of CAR-HEMATOTOX and a Simplified Version Predict Survival in Patients with Large B-Cell Lymphoma Treated with Anti-CD19 CAR T-Cells: Data from CART-SIE Study","volume":"31","author":"Stella","year":"2025","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.isci.2026.117255_bib22","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1038\/s41591-023-02415-3","article-title":"Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia","volume":"29","author":"Anderson","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117255_bib23","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41467-019-13880-1","article-title":"Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy","volume":"11","author":"Sheih","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117255_bib24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1158\/2643-3230.BCD-21-0029","article-title":"Circulating Tumor DNA in Lymphoma: Principles and Future Directions","volume":"3","author":"Roschewski","year":"2022","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.isci.2026.117255_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008450","article-title":"Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy","volume":"12","author":"Zou","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2026.117255_bib26","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1016\/j.jcyt.2020.03.291","article-title":"The challenges of potency assay development for cell and gene therapy products","volume":"22","author":"Gianelli","year":"2020","journal-title":"Cytotherapy"},{"key":"10.1016\/j.isci.2026.117255_bib27","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117255_bib28","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nm.2446","article-title":"A human memory T cell subset with stem cell\u2013like properties","volume":"17","author":"Gattinoni","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117255_bib29","doi-asserted-by":"crossref","first-page":"55","DOI":"10.7326\/M14-0697","article-title":"Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement","volume":"162","author":"Collins","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.isci.2026.117255_bib30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.7326\/M18-1376","article-title":"PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction Model Studies","volume":"170","author":"Wolff","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.isci.2026.117255_bib31","first-page":"e549","article-title":"Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension","volume":"2","author":"Cruz Rivera","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117255_bib32","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12916-019-1466-7","article-title":"Calibration: the Achilles heel of predictive analytics","volume":"17","author":"Van Calster","year":"2019","journal-title":"BMC Med."},{"key":"10.1016\/j.isci.2026.117255_bib33","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0272989X06295361","article-title":"Decision Curve Analysis: A Novel Method for Evaluating Prediction Models","volume":"26","author":"Vickers","year":"2006","journal-title":"Med. Decis. Mak."},{"key":"10.1016\/j.isci.2026.117255_bib34","doi-asserted-by":"crossref","first-page":"176618","DOI":"10.1016\/j.ejphar.2024.176618","article-title":"Improving chimeric antigen receptor T-cell therapies by using artificial intelligence and internet of things technologies: A narrative review","volume":"974","author":"Boretti","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.isci.2026.117255_bib35","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.3390\/jcm13113202","article-title":"CAR-T-Cell-Based Cancer Immunotherapies: Potentials, Limitations, and Future Prospects","volume":"13","author":"Choudhery","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.isci.2026.117255_bib36","doi-asserted-by":"crossref","first-page":"6","DOI":"10.46989\/001c.124277","article-title":"Overview of approved CAR-T products and utility in clinical practice","volume":"6","author":"Bhaskar","year":"2024","journal-title":"Clin. Hematol. Int."},{"key":"10.1016\/j.isci.2026.117255_bib37","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/bloodadvances.2019000525","article-title":"Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed\/refractory DLBCL","volume":"4","author":"Awasthi","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.isci.2026.117255_bib38","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.117255_bib39","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.isci.2026.117255_bib40","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.isci.2026.117255_bib41","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.117255_bib42","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117255_bib43","doi-asserted-by":"crossref","first-page":"1610794","DOI":"10.3389\/frhem.2025.1610794","article-title":"Advances in Chimeric Antigen Receptor T-cell therapy for hematologic malignancies and autoimmune conditions: a review of the 2024 American Society of Hematology Annual Meeting","volume":"4","author":"Davis","year":"2025","journal-title":"Front. Hematol."},{"key":"10.1016\/j.isci.2026.117255_bib44","article-title":"CAR-T cells in the treatment of multiple myeloma: an encouraging cell therapy","volume":"16","author":"Yu","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.117255_bib45","doi-asserted-by":"crossref","first-page":"1650568","DOI":"10.3389\/fimmu.2025.1650568","article-title":"Long-term follow-up of patients with relapsed\/refractory multiple myeloma after BCMA CAR-T-cell therapy","volume":"16","author":"Hao","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.117255_bib46","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40164-025-00643-6","article-title":"Mechanisms of resistance to CAR-T cell therapy in multiple myeloma: latest updates from the 2024 ASH annual meeting","volume":"14","author":"Hu","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.isci.2026.117255_bib47","doi-asserted-by":"crossref","first-page":"1583116","DOI":"10.3389\/fimmu.2025.1583116","article-title":"CAR-T cell therapy clinical trials: global progress, challenges, and future directions from ClinicalTrials.gov insights","volume":"16","author":"Cao","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.117255_bib48","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1186\/s12967-025-06543-x","article-title":"Key predictors of long-term outcomes in BCMA-targeted CAR-T therapy for relapsed\/refractory multiple myeloma","volume":"23","author":"An","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.isci.2026.117255_bib49","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/ejh.70025","article-title":"From Trials to Practice: A 2025 Review of Idecabtagene Vicleucel and Ciltacabtagene Autoleucel Efficacy Across Clinical Studies and Real-World Evidence","volume":"115","author":"Pleitez","year":"2025","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.isci.2026.117255_bib50","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41408-024-01191-8","article-title":"CAR-T cell therapy in Multiple Myeloma: current status and future challenges","volume":"14","author":"Swan","year":"2024","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.isci.2026.117255_bib51","doi-asserted-by":"crossref","first-page":"1607778","DOI":"10.3389\/fimmu.2025.1607778","article-title":"Case Report: Summary of multiple CAR-T expansions in anti-BCMA\/GPRC5D bispecific CAR-T cell therapy for multiple myeloma","volume":"16","author":"Wei","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.117255_bib52","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s12032-025-02753-x","article-title":"BCMA-targeted therapies in multiple myeloma: advances, challenges and future prospects","volume":"42","author":"Amin","year":"2025","journal-title":"Med. Oncol."},{"key":"10.1016\/j.isci.2026.117255_bib53","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41409-024-02446-5","article-title":"Role of the CIBMTR biorepository and registry in precision transplantation research","volume":"60","author":"Guerrettaz","year":"2025","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.isci.2026.117255_bib54","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1055\/a-2491-3652","article-title":"Basic Concepts and Indications of CAR T Cells","volume":"45","author":"van den Berg","year":"2025","journal-title":"H\u00e4mostaseologie"},{"key":"10.1016\/j.isci.2026.117255_bib55","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.948125","article-title":"A Review of CAR T Cells and Adoptive T-Cell Therapies in Lymphoid and Solid Organ Malignancies","volume":"31","author":"Parums","year":"2025","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.isci.2026.117255_bib56","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s40164-024-00536-0","article-title":"CAR-T cell combination therapies in hematologic malignancies","volume":"13","author":"Zhou","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.isci.2026.117255_bib57","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41408-024-01193-6","article-title":"Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies","volume":"14","author":"Tao","year":"2024","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.isci.2026.117255_bib58","doi-asserted-by":"crossref","first-page":"349.e1","DOI":"10.1016\/j.jtct.2025.02.009","article-title":"Awakening from REMS: ASTCT 80\/20 Ongoing Recommendations for Safe Use of Chimeric Antigen Receptor T Cells","volume":"31","author":"Locke","year":"2025","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.isci.2026.117255_bib59","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.isci.2026.117255_bib60","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol."},{"issue":"Supplement 1","key":"10.1016\/j.isci.2026.117255_bib61","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1182\/blood-2024-204207","article-title":"Efficacy and Safety of Tisagenlecleucel in Patients with Relapsed\/Refractory Follicular Lymphoma: A Real-World Analysis from the Center for Blood and Marrow Transplant Research (CIBMTR) Registry","volume":"144","author":"Landsburg","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.117255_bib62","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117255_bib63","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1182\/bloodadvances.2023011793","article-title":"Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma","volume":"8","author":"Choe","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.isci.2026.117255_bib64","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma","volume":"388","author":"Paula","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117255_bib65","first-page":"3","article-title":"Ciltacabtagene Autoleucel (Carvykti)","author":"CADTH","year":"2023","journal-title":"Can. J. Heal. Technol."},{"key":"10.1016\/j.isci.2026.117255_bib66","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s44272-025-00044-0","article-title":"Management of Cytokine Release Syndrome (CRS) following CAR T-cell therapy: a comprehensive review","volume":"4","author":"Zhang","year":"2025","journal-title":"Clin. Cancer Bull."},{"key":"10.1016\/j.isci.2026.117255_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2025.1553966","article-title":"Management strategies for CAR-T cell therapy-related toxicities: results from a survey in Greece","volume":"12","author":"Gavriilaki","year":"2025","journal-title":"Front. Med."},{"key":"10.1016\/j.isci.2026.117255_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2025.1582975","article-title":"Toxicities associated with lymphoma-targeting bispecific antibodies\u2014a review","volume":"12","author":"Doig","year":"2025","journal-title":"Front. Med."},{"key":"10.1016\/j.isci.2026.117255_bib69","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jtct.2025.09.028","article-title":"Management Practices of CAR T-cell-Related Inflammatory Toxicities: A Survey of Pediatric CAR T-cell Providers","volume":"32","author":"McNerney","year":"2025","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.isci.2026.117255_bib70","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.hoc.2023.05.010","article-title":"Toxicities of Chimeric Antigen Receptor T-Cells","volume":"37","author":"Epperly","year":"2023","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"10.1016\/j.isci.2026.117255_bib71","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/s43018-024-00826-w","article-title":"Deciphering the response to BCMA CAR T cell therapy","volume":"5","author":"Hassan","year":"2024","journal-title":"Nat. Cancer"},{"issue":"Supplement 1","key":"10.1016\/j.isci.2026.117255_bib72","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1182\/blood-2024-210020","article-title":"Elucidating Structural Epitope Mapping and Soluble BCMA in the Microenvironment: Impact on Anti-BCMA CAR-T Cell Functionality","volume":"144","author":"Mu","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.117255_bib73","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40164-025-00651-6","article-title":"Breakthroughs of CAR T-cell therapy in acute myeloid leukemia: updates from ASH 2024","volume":"14","author":"Zhang","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.isci.2026.117255_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1633644","article-title":"Real-world Australian experience with tisagenlecleucel for relapsed\/refractory diffuse large B-cell lymphoma\u2014importance of pre-CAR-T optimization","volume":"15","author":"Ho","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.isci.2026.117255_bib75","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jcyt.2025.05.005","article-title":"CD8 and CD4 CAR-T cells are associated with outcome and toxicity of tisagenlecleucel in central nervous system lymphoma","volume":"27","author":"Samara","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.isci.2026.117255_bib76","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/s41409-025-02679-y","article-title":"ICANS risk model in CD19 CAR-T therapy: insights from serum and CSF cytokine profiling","volume":"60","author":"Gomez-Llobell","year":"2025","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.isci.2026.117255_bib77","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1182\/bloodadvances.2024015014","article-title":"Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis","volume":"9","author":"Ahmed","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.isci.2026.117255_bib78","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/s41375-025-02532-7","article-title":"Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3","volume":"39","author":"Shah","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.isci.2026.117255_bib79","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1200\/JCO-25-00399","article-title":"Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed\/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study","volume":"43","author":"Kamdar","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117255_bib80","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1182\/bloodadvances.2024015262","article-title":"Lisocabtagene maraleucel for R\/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study","volume":"9","author":"Sehgal","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.isci.2026.117255_bib81","doi-asserted-by":"crossref","first-page":"6154","DOI":"10.1038\/s41467-025-60980-2","article-title":"Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma","volume":"16","author":"Atanackovic","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117255_bib82","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO-25-00760","article-title":"Long-Term (\u22655-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed\/Refractory Multiple Myeloma","volume":"43","author":"Jagannath","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117255_bib83","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/j.clml.2025.09.015","article-title":"Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial","volume":"26","author":"Kamboj","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.isci.2026.117255_bib84","article-title":"Efficacy and safety of CD19 combined with CD22 or CD20 chimeric antigen receptor T-cell therapy for hematological malignancies","volume":"16","author":"Yuan","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.117255_bib85","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1186\/s12967-025-06567-3","article-title":"Efficacy and safety of a novel CD19, CD22 dual-targeted fully human loop bi-CAR-T for the treatment of relapsed\/refractory B cell non-Hodgkin lymphoma","volume":"23","author":"Wang","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.isci.2026.117255_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1478888","article-title":"The efficacy and safety of CD7 chimeric antigen receptor T-cell therapy for hematologic malignancies: a systematic review and meta-analysis","volume":"14","author":"Liu","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.isci.2026.117255_bib87","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1016\/j.ymthe.2025.03.040","article-title":"Clinical development of allogeneic chimeric antigen receptor \u03b1\u03b2-T cells","volume":"33","author":"Georgiadis","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.isci.2026.117255_bib88","first-page":"100677","article-title":"Emerging trends in clinical allogeneic CAR cell therapy","volume":"6","author":"Li","year":"2025","journal-title":"M\u00e9d. Sur"},{"key":"10.1016\/j.isci.2026.117255_bib89","doi-asserted-by":"crossref","first-page":"1643941","DOI":"10.3389\/fimmu.2025.1643941","article-title":"Current strategies for armoring chimeric antigen receptor T-cells to overcome barriers of the solid tumor microenvironment","volume":"16","author":"Yang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.117255_bib90","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.1158\/1078-0432.CCR-24-0830","article-title":"Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma","volume":"30","author":"Hubbeling","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117255_bib91","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1038\/s41591-020-01157-w","article-title":"Using single-cell analysis to predict CAR T cell outcomes","volume":"26","author":"Ramakrishna","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117255_bib92","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell\u2013related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.117255_bib93","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1471-2105-7-91","article-title":"Bias in error estimation when using cross-validation for model selection","volume":"7","author":"Varma","year":"2006","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.isci.2026.117255_bib94","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12874-018-0482-1","article-title":"DeepSurv: personalized treatment recommender system using a Cox proportional hazards deep neural network","volume":"18","author":"Katzman","year":"2018","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.isci.2026.117255_bib95","first-page":"16","article-title":"Smart CAR-T Nanosymbionts: archetypes and proto-models. Front Immunol","author":"Baena","year":"2025","journal-title":"Volume"},{"key":"10.1016\/j.isci.2026.117255_bib96","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1200\/JCO.23.02232","article-title":"Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed\/Refractory Multiple Myeloma","volume":"42","author":"Gagelmann","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117255_bib97","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009220","article-title":"EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed\/refractory multiple myeloma","volume":"12","author":"Frenking","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2026.117255_bib98","first-page":"222","article-title":"Early transcriptional effects of inflammatory cytokines reveal highly redundant cytokine networks","author":"Lee","year":"2025","journal-title":"J. Exp. Med."},{"issue":"Supplement_1","key":"10.1016\/j.isci.2026.117255_bib99","doi-asserted-by":"crossref","first-page":"i356","DOI":"10.1093\/ecco-jcc\/jjae190.0190","article-title":"P0016 Comprehensive Characterization of local Cytokine Signatures in Ulcerative Colitis in Deep Remission","volume":"19","author":"Rogoll","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.isci.2026.117255_bib100","doi-asserted-by":"crossref","first-page":"7830","DOI":"10.1038\/s41598-024-82992-6","article-title":"Cytokines and inflammatory biomarkers and their association with post-operative delirium: a meta-analysis and systematic review","volume":"15","author":"Mosharaf","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2026.117255_bib101","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s12017-025-08877-7","article-title":"Mechanistic Study of Jaceosidin in Regulating Secondary Inflammation After Spinal Cord Injury in Mouse by Inhibiting PKM2 Activity","volume":"27","author":"Dai","year":"2025","journal-title":"Neuromolecular Med."},{"key":"10.1016\/j.isci.2026.117255_bib102","doi-asserted-by":"crossref","first-page":"152740","DOI":"10.1016\/j.semarthrit.2025.152740","article-title":"Personalised treatment of rheumatoid arthritis based on cytokine profiles and synovial tissue signatures: potentials and challenges","volume":"73","author":"Avouac","year":"2025","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.isci.2026.117255_bib103","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41422-025-01171-y","article-title":"Trained immunity: induction of an inflammatory memory in disease","volume":"35","author":"Schl\u00fcter","year":"2025","journal-title":"Cell Res."},{"key":"10.1016\/j.isci.2026.117255_bib104","article-title":"Editorial: Unraveling the molecular mechanisms of cytokine signaling in regulating inflammatory diseases","volume":"16","author":"Zheng","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.117255_bib105","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1158\/1078-0432.CCR-15-2825","article-title":"Molecular Profile and FDG-PET\/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma","volume":"22","author":"Cottereau","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117255_bib106","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.221362","article-title":"Chimeric Antigen Receptor T-Cell Therapy and I.maging Applications for Large B-Cell Lymphoma","volume":"307","author":"Mulholland","year":"2023","journal-title":"Radiology"},{"key":"10.1016\/j.isci.2026.117255_bib107","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70029","article-title":"Baseline Tumor Burden Assessed With AI-Guided PET\/CT Total Metabolic Tumor Volume (TMTV) and LDH Levels Predict Efficacy of CAR-T in Aggressive B-Cell Lymphoma","volume":"43","author":"Galli","year":"2025","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.isci.2026.117255_bib108","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1148\/radiol.2015151169","article-title":"Radiomics: Images Are More than Pictures, They Are Data","volume":"278","author":"Gillies","year":"2016","journal-title":"Radiology"},{"key":"10.1016\/j.isci.2026.117255_bib109","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.isci.2026.117255_bib110","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1148\/radiol.2020191145","article-title":"The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping","volume":"295","author":"Zwanenburg","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.isci.2026.117255_bib111","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.2967\/jnumed.117.199935","article-title":"A Postreconstruction Harmonization Method for Multicenter Radiomic Studies in PET","volume":"59","author":"Orlhac","year":"2018","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.isci.2026.117255_bib112","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41592-020-01008-z","article-title":"nnU-Net: a self-configuring method for deep learning-based biomedical image segmentation","volume":"18","author":"Isensee","year":"2021","journal-title":"Nat. Methods"},{"key":"10.1016\/j.isci.2026.117255_bib113","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13550-024-01172-9","article-title":"Predicting survival, neurotoxicity and response in B-cell lymphoma patients treated with CAR-T therapy using an imaging features-based model","volume":"14","author":"Ferrer-Lores","year":"2024","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.isci.2026.117255_bib114","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.annonc.2025.03.006","article-title":"Artificial intelligence entering the pathology arena in oncology: current applications and future perspectives","volume":"36","author":"Marra","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.isci.2026.117255_bib115","doi-asserted-by":"crossref","first-page":"5702","DOI":"10.1016\/j.apsb.2025.05.036","article-title":"Application of artificial intelligence in laboratory hematology: Advances, challenges, and prospects","volume":"15","author":"Liao","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.isci.2026.117255_bib116","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/ijlh.14533","article-title":"Digital Pathology in Hematopathology: From Vision to Deployment","volume":"48","author":"Shean","year":"2025","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.isci.2026.117255_bib117","article-title":"Mathematical models and computational approaches in CAR-T therapeutics","volume":"16","author":"Putignano","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.117255_bib118","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1493329","article-title":"Multi-targeted, NOT gated CAR-T cells as a strategy to protect normal lineages for blood cancer therapy","volume":"16","author":"DiAndreth","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.117255_bib119","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1615212","article-title":"Tracing the development of CAR-T cell design: from concept to next-generation platforms","volume":"16","author":"Alsaieedi","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.117255_bib120","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jcyt.2025.05.010","article-title":"The next innovations in chimeric antigen receptor T cell immunotherapies for cancer","volume":"27","author":"Anupindi","year":"2025","journal-title":"Cytotherapy"},{"issue":"Supplement 1","key":"10.1016\/j.isci.2026.117255_bib121","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1182\/blood-2024-206248","article-title":"Artificial Intelligence-Powered Digital Pathology to Improve Diagnosis and Personalized Prognostic Assessment in Patient with Myeloid Neoplasms","volume":"144","author":"Asti","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.117255_bib122","doi-asserted-by":"crossref","first-page":"5641","DOI":"10.1182\/bloodadvances.2025016689","article-title":"Population-based validation of the CAR-HEMATOTOX for hematotoxicity, infections and survival after CART in R\/R LBCL","volume":"9","author":"de Boer","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.isci.2026.117255_bib123","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41698-025-00886-w","article-title":"Multi-omics in immunotherapy research for HNSCC: present situation and future perspectives","volume":"9","author":"Liu","year":"2025","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.isci.2026.117255_bib124","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s00259-024-06616-x","article-title":"TMTV-Net: fully automated total metabolic tumor volume segmentation in lymphoma PET\/CT images - a multi-center generalizability analysis","volume":"51","author":"Yousefirizi","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.isci.2026.117255_bib125","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s12149-024-01923-7","article-title":"The effect of harmonization on the variability of PET radiomic features extracted using various segmentation methods","volume":"38","author":"Hosseini","year":"2024","journal-title":"Ann. Nucl. Med."},{"key":"10.1016\/j.isci.2026.117255_bib126","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.ymthe.2024.03.023","article-title":"High-multiplex single-cell imaging analysis reveals tumor immune contexture associated with clinical outcomes after CAR T cell therapy","volume":"32","author":"Jin","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.isci.2026.117255_bib127","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1158\/0008-5472.CAN-23-1698","article-title":"Integrating AI-Powered Digital Pathology and Imaging Mass Cytometry Identifies Key Classifiers of Tumor Cells, Stroma, and Immune Cells in Non\u2013Small Cell Lung Cancer","volume":"84","author":"Rigamonti","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.117255_bib128","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1597888","article-title":"New insights on potency assays from recent advances and discoveries in CAR T-cell therapy","volume":"16","author":"Shao","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.isci.2026.117255_bib129","doi-asserted-by":"crossref","first-page":"113561","DOI":"10.1016\/j.jconrel.2025.02.057","article-title":"Automated manufacturing of cell therapies","volume":"381","author":"Melocchi","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.isci.2026.117255_bib130","doi-asserted-by":"crossref","first-page":"101635","DOI":"10.1016\/j.beha.2025.101635","article-title":"Tumor microenvironment in CAR-T cell therapy for lymphoma","volume":"38","author":"Zhu","year":"2025","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.isci.2026.117255_bib131","doi-asserted-by":"crossref","first-page":"106084","DOI":"10.1016\/j.compbiomed.2022.106084","article-title":"RCMNet: A deep learning model assists CAR-T therapy for leukemia","volume":"150","author":"Zhang","year":"2022","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.isci.2026.117255_bib132","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"Br. Med. J."},{"key":"10.1016\/j.isci.2026.117255_bib133","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41746-025-01836-3","article-title":"A scoping review of the governance of federated learning in healthcare","volume":"8","author":"Eden","year":"2025","journal-title":"npj Digit. Med."},{"key":"10.1016\/j.isci.2026.117255_bib134","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.12771\/emj.2025.00668","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods: a Korean translation","volume":"48","author":"Collins","year":"2025","journal-title":"Ewha Med. J."},{"key":"10.1016\/j.isci.2026.117255_bib135","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s43856-024-00492-0","article-title":"Reporting guidelines in medical artificial intelligence: A systematic review and meta-analysis","volume":"4","author":"Kolbinger","year":"2024","journal-title":"Commun. Med."},{"key":"10.1016\/j.isci.2026.117255_bib136","article-title":"Artificial Intelligence and Machine Learning Innovations to Improve Design and Representativeness in Oncology Clinical Trials","volume":"45","author":"Azenkot","year":"2025","journal-title":"Am Soc Clin Oncol Educ B"},{"key":"10.1016\/j.isci.2026.117255_bib137","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40644-022-00476-0","article-title":"Full automation of total metabolic tumor volume from FDG-PET\/CT in DLBCL for baseline risk assessments","volume":"22","author":"Jemaa","year":"2022","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.isci.2026.117255_bib138","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/s41591-019-0508-1","article-title":"Clinical-grade computational pathology using weakly supervised deep learning on whole slide images","volume":"25","author":"Campanella","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117255_bib139","doi-asserted-by":"crossref","first-page":"101813","DOI":"10.1016\/j.media.2020.101813","article-title":"Deep neural network models for computational histopathology: A survey","volume":"67","author":"Srinidhi","year":"2021","journal-title":"Med. Image Anal."},{"key":"10.1016\/j.isci.2026.117255_bib140","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.806603","article-title":"Deep Learning-Based Mapping of Tumor Infiltrating Lymphocytes in Whole Slide Images of 23 Types of Cancer","volume":"11","author":"Abousamra","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.isci.2026.117255_bib141","doi-asserted-by":"crossref","first-page":"S180","DOI":"10.1016\/j.jtct.2023.12.234","article-title":"Identification and Prediction of Severe Hematologic Toxicity after CAR T-Cell Therapy Using Machine Learning-Based Time-Series Clustering","volume":"30","author":"Liang","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.isci.2026.117255_bib142","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1182\/blood-2016-03-635219","article-title":"Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma","volume":"127","author":"Roschewski","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.117255_bib143","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/10428194.2018.1485916","article-title":"Circulating tumor DNA for disease monitoring in the era of CAR T-cell therapy","volume":"60","author":"Blombery","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.isci.2026.117255_bib144","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.134612","article-title":"Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy","volume":"5","author":"Chen","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.isci.2026.117255_bib145","first-page":"1534","article-title":"Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma","volume":"25","author":"Roschewski","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117255_bib146","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression Models and Life-Tables","volume":"34","year":"1972","journal-title":"J. R. Stat. Soc. Ser. B"},{"issue":"Supplement","key":"10.1016\/j.isci.2026.117255_bib147","doi-asserted-by":"crossref","first-page":"S208","DOI":"10.1016\/j.jtct.2025.01.321","article-title":"Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (Pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (Tx) from the Phase 3, Randomized Transform","volume":"31","author":"Stepan","year":"2025","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.isci.2026.117255_bib148","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41408-025-01338-1","article-title":"Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma","volume":"15","author":"Winkelmann","year":"2025","journal-title":"Blood Cancer J."},{"issue":"16_suppl","key":"10.1016\/j.isci.2026.117255_bib149","first-page":"43","article-title":"Circulating tumor DNA assessment in patients with early-stage classical Hodgkin lymphoma treated with combination of brentuximab vedotin and nivolumab","volume":"7040","author":"Lynch","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117255_bib150","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70159","article-title":"Prognostic significance of PET\/CT for CAR T cell therapy in relapsed\/refractory multiple myeloma","volume":"9","author":"Born","year":"2025","journal-title":"HemaSphere"},{"key":"10.1016\/j.isci.2026.117255_bib151","doi-asserted-by":"crossref","DOI":"10.3389\/frhem.2025.1618331","article-title":"Pre-infusion ferritin a predictive biomarker for CAR T-cell therapy in R\/R multiple myeloma","volume":"4","author":"Moreno-Cortes","year":"2025","journal-title":"Front Hematol"},{"key":"10.1016\/j.isci.2026.117255_bib152","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13550-025-01201-1","article-title":"Liver-FDG-uptake augments early PET\/CT prognostic value for CD19-targeted CAR-T cell therapy in diffuse large B cell lymphoma","volume":"15","author":"Beck","year":"2025","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.isci.2026.117255_bib153","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1038\/s41375-025-02688-2","article-title":"Integration of [18F]FDG-PET radiomics with liquid biopsy improves outcome prediction in newly diagnosed diffuse large B-cell lymphoma","volume":"39","author":"Dondolin","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.isci.2026.117255_bib154","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.3390\/cancers17111827","article-title":"18F-FDG PET\/CT Radiomics for Predicting Therapy Response in Primary Mediastinal B-Cell Lymphoma: A Bi-Centric Pilot Study","volume":"17","author":"Esposito","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.isci.2026.117255_bib155","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40644-025-00888-8","article-title":"Prognostic value of early post-treatment 18F-FDG PET\/CT in diffuse large B-cell lymphoma patients receiving chimeric antigen receptor T-cell therapy","volume":"25","author":"Mirshahvalad","year":"2025","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.isci.2026.117255_bib156","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.117255_bib157","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1038\/s41591-018-0177-5","article-title":"Classification and mutation prediction from non\u2013small cell lung cancer histopathology images using deep learning","volume":"24","author":"Coudray","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117255_bib158","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41551-025-01357-0","article-title":"Identifying perturbations that boost T-cell infiltration into tumours via counterfactual learning of their spatial proteomic profiles","volume":"9","author":"Wang","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.isci.2026.117255_bib159","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41746-025-01471-y","article-title":"Convergence of evolving artificial intelligence and machine learning techniques in precision oncology","volume":"8","author":"Fountzilas","year":"2025","journal-title":"NPJ Digit. Med."},{"key":"10.1016\/j.isci.2026.117255_bib160","doi-asserted-by":"crossref","first-page":"102030","DOI":"10.1016\/j.xcrm.2025.102030","article-title":"Practical microenvironment classification in diffuse large B cell lymphoma using digital pathology","volume":"6","author":"Wang","year":"2025","journal-title":"Cell Reports Med"},{"key":"10.1016\/j.isci.2026.117255_bib161","doi-asserted-by":"crossref","first-page":"114421","DOI":"10.1016\/j.addr.2022.114421","article-title":"Cellular kinetics: A clinical and computational review of CAR-T cell pharmacology","volume":"188","author":"Qi","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.isci.2026.117255_bib162","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41746-022-00694-7","article-title":"Health digital twins as tools for precision medicine: Considerations for computation, implementation, and regulation","volume":"5","author":"Venkatesh","year":"2022","journal-title":"NPJ Digit. Med."},{"key":"10.1016\/j.isci.2026.117255_bib163","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41591-018-0310-5","article-title":"Guidelines for reinforcement learning in healthcare","volume":"25","author":"Gottesman","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117255_bib164","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1182\/bloodadvances.2023012263","article-title":"CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure?","volume":"9","author":"Maciocia","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.isci.2026.117255_bib165","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/s41409-025-02637-8","article-title":"Harmonisation of quality control tests for academic production of CAR-T cells: a position paper from the WP-bioproduction of the UNITC consortium","volume":"60","author":"Marton","year":"2025","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.isci.2026.117255_bib166","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1016\/j.ymthe.2025.04.006","article-title":"High-dimensional temporal mapping of CAR T cells reveals phenotypic and functional remodeling during manufacturing","volume":"33","author":"Cadinanos-Garai","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.isci.2026.117255_bib167","doi-asserted-by":"crossref","DOI":"10.1080\/20565623.2025.2483613","article-title":"CAR-T cell therapies: patient access and affordability solutions","volume":"11","author":"Gon\u00e7alves","year":"2025","journal-title":"Futur Sci OA"},{"key":"10.1016\/j.isci.2026.117255_bib168","article-title":"Navigating Healthcare AI Governance: the Comprehensive Algorithmic Oversight and Stewardship Framework for Risk and Equity","author":"Kumar","year":"2025","journal-title":"Health Care Anal."},{"key":"10.1016\/j.isci.2026.117255_bib169","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jtct.2025.09.044","article-title":"Under the Hood: Evidence-Based Review of Allogeneic Chimeric Antigen Receptor T Cells for Hematologic Malignancies","volume":"32","author":"Cheema","year":"2025","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.isci.2026.117255_bib170","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1585556","article-title":"Allogeneic CAR-engineered cellular therapy for relapsed and refractory large B cell lymphoma: a systematic review and meta-analysis","volume":"16","author":"Biederst\u00e4dt","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.117255_bib171","doi-asserted-by":"crossref","first-page":"S406","DOI":"10.1016\/j.jtct.2025.01.625","article-title":"An Endothelial Activation and Stress Index (EASIX) Based Predictive Model for Neurotoxicity and Cytokine Release Syndrome (CRS) after B-Cell Maturation Antigen (BCMA)- Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed\/Refractory Multipl","volume":"31","author":"Goel","year":"2025","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.isci.2026.117255_bib172","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00277-025-06190-8","article-title":"The predictive power of (18)F-FDG PET\/CT two-lesions radiomics and conventional models in classical Hodgkin\u2019s Lymphoma: a comparative retrospectively-validated study","volume":"104","author":"Triumbari","year":"2025","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.isci.2026.117255_bib173","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41698-025-00857-1","article-title":"Quantifying and interpreting biologically meaningful spatial signatures within tumor microenvironments","volume":"9","author":"Jing","year":"2025","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.isci.2026.117255_bib174","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13046-022-02540-w","article-title":"Dose fractionation of CAR-T cells. A systematic review of clinical outcomes","volume":"42","author":"Frigault","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117255_bib175","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","article-title":"Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL","volume":"56","author":"Sheth","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.isci.2026.117255_bib176","doi-asserted-by":"crossref","first-page":"100151","DOI":"10.1016\/j.bbadva.2025.100151","article-title":"Quality assessment strategy development and analytical method selection of GMP grade biological drugs for gene and cell therapy","volume":"7","author":"Yang","year":"2025","journal-title":"BBA Adv."},{"key":"10.1016\/j.isci.2026.117255_bib177","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s12185-025-03957-7","article-title":"Simple and early prediction of severe CAR-T-related adverse events after Axi-cel infusion by initial high fever","volume":"122","author":"Wakabayashi","year":"2025","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.isci.2026.117255_bib178","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2024015788","article-title":"Measurable Residual Disease Detection after CAR-T May Predict Response in Patients with Large B-cell Lymphoma","author":"Krasnow","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.isci.2026.117255_bib179","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/s41467-025-56486-6","article-title":"Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma","volume":"16","author":"Hosoya","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117255_bib180","doi-asserted-by":"crossref","first-page":"4819","DOI":"10.1038\/s41467-025-59904-x","article-title":"Durable response to CAR T is associated with elevated activation and clonotypic expansion of the cytotoxic native T cell repertoire","volume":"16","author":"Cheloni","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117255_bib181","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1007\/s00277-025-06409-8","article-title":"Feasibility analysis of metabolic parameters based on baseline (18)F-FDG PET\/CT to predict heterogeneity and recurrence of diffuse large B-cell lymphoma","volume":"104","author":"Ge","year":"2025","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.isci.2026.117255_bib182","doi-asserted-by":"crossref","first-page":"25752","DOI":"10.1038\/s41598-024-77210-2","article-title":"Patient-reported outcomes of chimeric antigen receptor T-cell therapy in hematologic malignancies: a systematic review and meta-analysis","volume":"14","author":"Park","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2026.117255_bib183","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000802","article-title":"Chimeric Antigen Receptor T-cell Therapy in Hematologic Malignancies and Patient-reported Outcomes: A Scoping Review","volume":"6","author":"Efficace","year":"2022","journal-title":"HemaSphere"},{"key":"10.1016\/j.isci.2026.117255_bib184","doi-asserted-by":"crossref","first-page":"1219.e1","DOI":"10.1016\/j.jtct.2024.09.013","article-title":"Prospective Assessment of Quality of Life and Patient-Reported Toxicities Over the First Year After Chimeric Antigen Receptor T-Cell Therapy","volume":"30","author":"Hoogland","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.isci.2026.117255_bib185","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","article-title":"Validity and Reliability of the US National Cancer Institute\u2019s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"1","author":"Dueck","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.isci.2026.117255_bib186","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.isci.2026.117255_bib187","doi-asserted-by":"crossref","first-page":"6380","DOI":"10.1182\/bloodadvances.2025017081","article-title":"Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe","volume":"9","author":"Pennings","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.isci.2026.117255_bib188","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13045-024-01540-x","article-title":"Conventional and novel [18F]FDG PET\/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma","volume":"17","author":"Leithner","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.isci.2026.117255_bib189","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/s41591-025-03532-x","article-title":"An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma","volume":"31","author":"Raj","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117255_bib190","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1080\/10428194.2024.2387731","article-title":"CAR T-cells in very elderly (\u226580 years) lymphoma patients: a DESCAR-T analysis","volume":"65","author":"Menez","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.isci.2026.117255_bib191","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1182\/bloodadvances.2024014732","article-title":"Outcome of high-grade B-cell lymphoma compared with other large B-cell lymphoma after CAR-T rescue: a DESCAR-T LYSA study","volume":"9","author":"Phina-Ziebin","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.isci.2026.117255_bib192","doi-asserted-by":"crossref","first-page":"100619","DOI":"10.1016\/j.ejro.2024.100619","article-title":"The predictive power of baseline metabolic and volumetric [18F]FDG PET parameters with different thresholds for early therapy failure and mortality risk in DLBCL patients undergoing CAR-T-cell therapy","volume":"14","author":"Novruzov","year":"2025","journal-title":"Eur. J. Radiol. Open"},{"key":"10.1016\/j.isci.2026.117255_bib193","article-title":"Calculating the sample size required for developing a clinical prediction model","volume":"368","author":"Riley","year":"2020","journal-title":"Br. Med. J."},{"key":"10.1016\/j.isci.2026.117255_bib194","article-title":"Effective MRD clearance and long-term survival with CD19 CAR-T in pediatric B-ALL patients with MRD positivity or chemotherapy intolerance","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.117255_bib195","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12943-025-02334-6","article-title":"Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy","volume":"24","author":"Lu","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.isci.2026.117255_bib196","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/ajh.27708","article-title":"Adult Acute Lymphoblastic Leukemia: 2025 Update on Diagnosis, Therapy, and Monitoring","volume":"100","author":"Kantarjian","year":"2025","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.isci.2026.117255_bib197","doi-asserted-by":"crossref","first-page":"351.e1","DOI":"10.1016\/j.jtct.2025.02.016","article-title":"Tisagenlecleucel in Practice: Real-World Lessons in Pediatric and Young Adult B-ALL","volume":"31","author":"McNerney","year":"2025","journal-title":"Transplant. Cell. Ther."},{"issue":"Supplement 1","key":"10.1016\/j.isci.2026.117255_bib198","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-189468","article-title":"In Vivo Anti-BCMA CAR T-Cell Expansion Kinetics Correlate with Early IMWG Response in RRMM: A Single Institution Study with Comparative Analysis of Idecabtagene Vicleucel and Ciltacabtagene Autoleucel","volume":"142","author":"Kocoglu","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.117255_bib199","doi-asserted-by":"crossref","first-page":"100663","DOI":"10.1016\/j.ejro.2025.100663","article-title":"[18F]FDG-PET\/CT in DLBCL-patients treated with CAR-T cell therapy: potential for defining patient prognosis","volume":"14","author":"Peters","year":"2025","journal-title":"Eur. J. Radiol. Open"},{"key":"10.1016\/j.isci.2026.117255_bib200","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1007\/s11596-025-00109-0","article-title":"Novel Prognostic Scoring Systems for Severe CRS after Anti-CD19 CAR-T-Cells in Acute B-Lymphoblastic Leukemia","volume":"45","author":"Ke","year":"2025","journal-title":"Curr. Med. Sci."},{"key":"10.1016\/j.isci.2026.117255_bib201","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1182\/bloodadvances.2025016712","article-title":"Sequential BCMA CAR T-cell therapy in refractory multiple myeloma","volume":"9","author":"Richardson","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.isci.2026.117255_bib202","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41746-025-01809-6","article-title":"Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapies","volume":"8","author":"Weirauch","year":"2025","journal-title":"NPJ Digit. Med."},{"key":"10.1016\/j.isci.2026.117255_bib203","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/cimb47050321","article-title":"The Potential Use of Digital Twin Technology for Advancing CAR-T Cell Therapy","volume":"47","author":"Aghamiri","year":"2025","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.isci.2026.117255_bib204","doi-asserted-by":"crossref","first-page":"101557","DOI":"10.1016\/j.beha.2024.101557","article-title":"Celebrating the registration of 9.000 patients treated with CAR T cells in the EBMT registry: Collection of real-world data in the context of hematopoietic cellular therapies","volume":"37","author":"Chabannon","year":"2024","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.isci.2026.117255_bib205","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jtct.2025.06.001","article-title":"Malignancies after Chimeric Antigen Receptor T Cell Therapy","volume":"31","author":"Mohty","year":"2025","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.isci.2026.117255_bib206","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101462","article-title":"Optimization of hypo-alloimmunogenic multispecific CAR-T and SARS-CoV-2-specific T cells for off-the-shelf adoptive cell therapy","volume":"33","author":"Ng","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.isci.2026.117255_bib207","doi-asserted-by":"crossref","first-page":"748","DOI":"10.2967\/jnumed.124.268186","article-title":"Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Ethical, Regulatory, and Socioeconomic Dimensions of Theranostic Digital Twins","volume":"66","author":"Strigari","year":"2025","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.isci.2026.117255_bib208","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s12935-024-03479-y","article-title":"Recent updates on allogeneic CAR-T cells in hematological malignancies","volume":"24","author":"Mansoori","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.isci.2026.117255_bib209","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1186\/s12913-024-11112-x","article-title":"Understanding the integration of artificial intelligence in healthcare organisations and systems through the NASSS framework: a qualitative study in a leading Canadian academic centre","volume":"24","author":"Alami","year":"2024","journal-title":"BMC Health Serv. Res."},{"key":"10.1016\/j.isci.2026.117255_bib210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pdig.0000418","article-title":"The NASSS (Non-Adoption, Abandonment, Scale-Up, Spread and Sustainability) framework use over time: A scoping review","volume":"4","author":"Shin","year":"2025","journal-title":"PLOS Digit. Health"},{"key":"10.1016\/j.isci.2026.117255_bib211","doi-asserted-by":"crossref","DOI":"10.2196\/56711","article-title":"Characterizing Behaviors That Influence the Implementation of Digital-Based Interventions in Health Care: Systematic Review","volume":"27","author":"Patel","year":"2025","journal-title":"J. Med. Internet Res."},{"key":"10.1016\/j.isci.2026.117255_bib212","doi-asserted-by":"crossref","first-page":"105153","DOI":"10.1016\/j.healthpol.2024.105153","article-title":"Availability and financing of CAR-T cell therapies: A cross-country comparative analysis","volume":"149","author":"Litvinova","year":"2024","journal-title":"Health Policy"},{"key":"10.1016\/j.isci.2026.117255_bib213","doi-asserted-by":"crossref","first-page":"105872","DOI":"10.1016\/j.ijmedinf.2025.105872","article-title":"Patient consent for the secondary use of health data in artificial intelligence (AI) models: A scoping review","volume":"198","author":"Moulaei","year":"2025","journal-title":"Int. J. Med. Inf."},{"key":"10.1016\/j.isci.2026.117255_bib214","doi-asserted-by":"crossref","first-page":"100686","DOI":"10.1016\/j.modpat.2024.100686","article-title":"Ethical and Bias Considerations in Artificial Intelligence\/Machine Learning","volume":"38","author":"Hanna","year":"2025","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.isci.2026.117255_bib215","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s12672-025-03307-3","article-title":"Application of artificial intelligence in medical imaging for tumor diagnosis and treatment: a comprehensive approach","volume":"16","author":"Huang","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.isci.2026.117255_bib216","doi-asserted-by":"crossref","first-page":"103265","DOI":"10.1016\/j.artmed.2025.103265","article-title":"Medical multimodal foundation models in clinical diagnosis and treatment: Applications, challenges, and future directions","volume":"170","author":"Sun","year":"2025","journal-title":"Artif. Intell. Med."},{"key":"10.1016\/j.isci.2026.117255_bib217","first-page":"13","article-title":"Predictive value of preclinical models for CAR-T cell therapy clinical trials: a systematic review and meta-analysis","author":"Andreu-Sanz","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2026.117255_bib218","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1007\/s11912-025-01698-8","article-title":"Artificial Intelligence and Decision-Making in Oncology: A Review of Ethical, Legal, and Informed Consent Challenges","volume":"27","author":"Froicu","year":"2025","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.isci.2026.117255_bib219","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(25)01268-1","article-title":"Pessoa C do \u00d3. AI in clinical trials is missing from CONSORT and SPIRIT 2025 guidelines","volume":"406","author":"Ribeiro Junior","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2026.117255_bib220","article-title":"Addressing the current challenges in the clinical application of AI-based Radiomics for cancer imaging","volume":"12","author":"Xu","year":"2025","journal-title":"Front. Med."},{"key":"10.1016\/j.isci.2026.117255_bib221","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12967-025-06139-5","article-title":"The clinical application of artificial intelligence in cancer precision treatment","volume":"23","author":"Wang","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.isci.2026.117255_bib222","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.2967\/jnumed.124.269425","article-title":"Summary Report of the SNMMI AI Task Force Radiomics Challenge 2024","volume":"66","author":"Boellaard","year":"2025","journal-title":"J. Nucl. Med."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226026337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226026337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T10:17:37Z","timestamp":1794478657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226026337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":222,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2589004226026337"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.117255","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intelligent immunotherapy: AI-driven optimization of CAR-T therapy in hematologic malignancies","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.117255","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117255"}}